[1] Derikx J.P., Poeze M., van Bijnen A.A., Buurman W.A., Heineman
E., Evidence for intestinal and liver epithelial cell injury in the
early phase of sepsis, Shock, 2007, 28, 544-548
Web of ScienceGoogle Scholar
[2] Azzopardi N., Fenech M., Piscopo T., Sepsis, the Liver and the
Gut, Sepsis–An Ongoing and Significant Challenge, InTech,
2012
Google Scholar
[3] Puleo F., Arvanitakis M., Van Gossum A., Preiser J.C., Gut failure
in the ICU, Semin Respir Crit Care Med., 2011, 32, 626-638
Web of ScienceGoogle Scholar
[4] Mammen J.M.V.M., Matthews J.B.M., Mucosal repair in the
gastrointestinal tract, Critical Care Medicine Healing Responses
in Critical Illness, 2003,31,S532-S537
Google Scholar
[5] Thim L., A new family of growth factor-like peptides: ‘trefoil’
disulphide loop structures as a common feature in breast
cancer associated peptide (pS2), pancreatic spasmolytic
polypeptide (PSP) and frog skin peptides (spasmolysins), FEBS
Lett., 1989, 250, 85-90
Google Scholar
[6] Hauser F., Poulsom R., Chinery R., Rogers L.A., Hanby
A.M., Wright N.A., et al., hP1.B, a human P-domain peptide
homologous with rat intestinal trefoil factor, is expressed also
in the ulcer-associated cell lineage and the uterus, Proc. Natl.
Acad. Sci. USA, 1993, 90, 6961-6965
Google Scholar
[7] Xian C.J., Howarth G.S., Mardell C.E., Cool J.C., Familari M.,
Read L.C., et al., Temporal changes in TFF3 expression and
jejunal morphology during methotrexate-induced damage and
repair, Am J Physiol, 1999,277, G785-G795
Google Scholar
[8] Babyatsky M.W., deBeaumont M., Thim L., Podolsky D.K., Oral
trefoil peptides protect against ethanol- and indomethacininduced
gastric injury in rats, Gastroenterology, 1996,110,
489-497
Google Scholar
[9] Schwarzberg H., Kalbacher H., Hoffmann W., Differential
behavioral effects of TFF peptides: Injections of synthetic
TFF3 into the ratamygdala, Pharmacol BiochemBehav,
1999,62,173-178
Google Scholar
[10] Goldstein B., Giroir B., Randolph A., International pediatric
sepsis consensus conference: Definitions for sepsis and organ
dysfunction in pediatrics, Pediatr Crit Care Med, 2005, 6, 2-8
CrossrefGoogle Scholar
[11] Leteurtre S., Martinot A., Duhamel A., Gauvin F., Grandbastien
B., Nam T.V., et al.. Development of a pediatric multiple organ
dysfunction score: use of two strategies, Med Decis Making,
1999, 19, 399-410
Google Scholar
[12] Ng E.W., Poon T.C., Lam H.S., Cheung H.M., Ma T.P., Chan K.Y.,
et al., Gut-Associated Biomarkers L-FABP, I-FABP, and TFF3 and
LIT Score for Diagnosis of Surgical Necrotizing Enterocolitis in
Preterm Infants, Ann Surg. , 2013, 258, 1111-1118
Google Scholar
[13] Vestergaard E.M., Poulsen S.S., Grønbaek H., Larsen
R., Nielsen A.M., Ejskjaer K., et al., Development and
evaluation of an ELISA for human trefoil factor 3, Clin Chem.,
2002,48,1689-1695
Google Scholar
[14] Moran P., Beasley H., Gorrell A., Martin E., Gribling P., Fuchs H.,
et al., Human recombinant soluble decay accelerating factor
inhibits complement activation in vitro and in vivo, J. Immunol.,
1992, 149, 1736-1743
Google Scholar
[15] Heeger P.S., Lalli P.N., Lin F., Valujskikh A., Liu J., Muqim N.,
et al., Decay-accelerating factor modulates induction of T cell
immunity, J. Exp. Med., 2005, 201, 1523-1530
Google Scholar
[16] Fink M.P., Delude R.L., Epithelial barrier dysfunction: a
unifying theme to explain the pathogenesis of multiple organ
dysfunction at the cellular level, Crit Care Clin 2005, 2, 177-196
Google Scholar
[17] Gatt M., Reddy B.S., MacFie J., Review article: bacterial
translocation in the critically ill–evidence and methods of
prevention, Aliment Pharmacol Ther., 2007, 25, 741-757
Web of ScienceGoogle Scholar
[18] Stephens R.C., Fidler K., Wilson P., Barclay G.R., Mythen M.G.,
Dixon G.L., et al., Endotoxin immunity and the development of
the systemic inflammatory response syndrome in critically ill
children, Intensive Care Med, 2006, 32, 286-294
Google Scholar
Comments (0)